TrialJournal for immunotherapy of cancer2021

Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: an open-label single-arm, phase II trial.

Yijun Hua et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.